Indivior与Supernus对等合并获双方股东批准 预计11月2日完成
Indivior（纳斯达克：INDV）与Supernus Pharmaceuticals（纳斯达克：SUPN）10月16日分别披露，两家公司已于10月15日召开特别股东大会，双方股东均批准了今年8月宣布的全股票对等合并。Indivior股东以85,455,705票赞成、5,563,744票反对、186,733票弃权通过股份发行议案（出席股份91,206,182股，发行在外股份118,031,934股，记录日为9月4日）；Supernus股东以48,249,532票赞成、235,601票反对、67,004票弃权通过合并协议，参与表决股份约占其已发行股份的83%。
按合并条款，Supernus股东每持有一股将换得1.5401股Indivior股份；Indivior股东将在交割前夕获得总额10亿美元的一次性特别现金股息，资金来自花旗银行6.5亿美元定期贷款承诺及合并后公司的手头现金。交割后，原Indivior股东与原Supernus股东将分别持有合并公司约56.5%和43.5%的股份（全稀释口径）。
合并后的公司将更名为Supernus, Inc.，继续以SUPN代码在纳斯达克交易，董事会由8名董事组成，Jack Khattar预计出任首席执行官，Timothy Dec预计出任首席财务官。交易预计11月2日完成，尚待《哈特-斯科特-罗迪诺法》等待期届满及纳斯达克上市批准等条件。合并将形成一家聚焦中枢神经系统疾病的多元化生物制药公司。
Indivior and Supernus Shareholders Approve Merger of Equals; Close Expected November 2
Indivior (Nasdaq: INDV) and Supernus Pharmaceuticals (Nasdaq: SUPN) disclosed on October 16 that shareholders of both companies approved their all-stock merger of equals, first announced in August 2026, at special meetings held October 15. Indivior shareholders approved the share-issuance proposal with 85,455,705 votes for, 5,563,744 against and 186,733 abstentions, with 91,206,182 shares represented out of 118,031,934 outstanding at the September 4 record date. Supernus stockholders adopted the merger agreement with 48,249,532 votes for, 235,601 against and 67,004 abstentions, representing about 83% of outstanding shares.
Under the merger terms, Supernus holders will receive 1.5401 Indivior shares for each Supernus share, and Indivior holders will receive a one-time special cash dividend of $1.0 billion in aggregate immediately before closing, funded by a $650 million Citibank term loan commitment plus combined-company cash on hand. After closing, Indivior holders are expected to own about 56.5% and Supernus holders about 43.5% of the combined company on a fully diluted basis.
The combined company will be named Supernus, Inc. and trade on Nasdaq under SUPN, with an eight-member board; Jack Khattar is expected to serve as chief executive and Timothy Dec as chief financial officer. The transaction is expected to close on November 2, 2026, subject to remaining conditions including expiration of the HSR waiting period and Nasdaq listing approval, creating a diversified, CNS-focused biopharmaceutical company.
发布：GSM·美国（发布链接）
图片来源：Indivior公司官方标志 / Indivior official logo
GSM Global · 本篇英文版 English edition of this story
